U.S., April 22 -- ClinicalTrials.gov registry received information related to the study (NCT07541638) titled 'Early Recognition of Progressive Lung Fibrosis in Systemic Rheumatic Diseases' on March 26... Read More
U.S., April 22 -- ClinicalTrials.gov registry received information related to the study (NCT07543393) titled 'Nudging for Anticoagulation Adherence in Atrial Fibrillation' on April 14. Brief Summary:... Read More
U.S., April 22 -- ClinicalTrials.gov registry received information related to the study (NCT07541157) titled 'Effect of Ashwagandha as Adjunct Therapy on BDNF and Cognitive Function in Schizophrenia P... Read More
Singapore, April 22 -- The Health Sciences Authority received information related to the study titled 'A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Olverembatinib Combi... Read More
Singapore, April 22 -- The Health Sciences Authority received information related to the study titled ''Establishing the role of mitomycin C and systemic non-steroidal anti-inflammatory drugs in the p... Read More
Singapore, April 22 -- The Health Sciences Authority received information related to the study titled 'IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-98650... Read More
Singapore, April 22 -- The Health Sciences Authority received information related to the study titled 'ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemother... Read More
Singapore, April 22 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safe... Read More
Singapore, April 22 -- The Health Sciences Authority received information related to the study titled 'A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) ... Read More
Singapore, April 22 -- The Health Sciences Authority received information related to the study titled 'DAREON®-Lung 1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig ... Read More